AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m.
The agreement between the companies involves rights in markets outside the US, along with the US royalties for the drugs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Covis Pharma, which currently commercialises all three medicines in the US, will own them after the completion of the transaction.
Delivered using a metered-dose inhaler, Alvesco is an anti-inflammatory maintenance therapy indicated for the treatment of persistent asthma.
Omnaris and Zetonna are formulated as nasal sprays for addressing nasal symptoms caused by seasonal allergic and allergic/non-allergic perennial rhinitis.
Alvesco, Omnaris and Zetonna together generated $106m in product sales last year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAstraZeneca Global Product and Portfolio Strategy executive vice-president Mark Mallon said: “One of our strategic objectives is to divest parts of our portfolio, allowing us to allocate resources to develop innovative new medicines to address unmet patient needs.
“Covis Pharma has strong capabilities in marketing medicines around the world, and our agreement with them means patients will continue to benefit from Alvesco, Omnaris and Zetonna.”
Under the terms of the agreement, Covis Pharma will pay $350m upon closing to AstraZeneca, which will also receive conditional sales-related payments of up to $21m over four years from next year.
Subject to customary closing conditions, the transaction is expected to close by the end of this year.
Covis Pharma CEO Michael Porter said: “This is an exciting milestone for Covis Pharma and aligned with our strategy to build a global respiratory/allergy franchise.
“When we acquired the US rights for Alvesco, Omnaris and Zetonna in 2017, we recognised the importance of these medicines in the respiratory and allergy therapeutic area and we look forward to extending our reach to meet the needs of patients and physicians around the world.”
Last month, AstraZeneca entered a similar deal with Grünenthal Group to sell select prescription medicine rights to its Nexium and Vimovo drugs for $922m.
